Stayble Therapeutics AB (publ) (STABL.ST)
SEK 0.49
(-4.22%)
SEK 0.49
(-4.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.19 Million SEK | 34.38% |
| 2022 | 3.86 Million SEK | 0.9% |
| 2021 | 3.83 Million SEK | 56.5% |
| 2020 | 2.44 Million SEK | -75.55% |
| 2019 | 10.01 Million SEK | 429.62% |
| 2018 | 1.89 Million SEK | 55.95% |
| 2017 | 1.21 Million SEK | 10.22% |
| 2016 | 1.1 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.55 Million SEK | 91.96% |
| 2024 Q1 | 1.85 Million SEK | -64.31% |
| 2023 FY | 5.19 Million SEK | 34.38% |
| 2023 Q4 | 5.19 Million SEK | -17.96% |
| 2023 Q2 | 4.19 Million SEK | -15.99% |
| 2023 Q1 | 4.99 Million SEK | 29.1% |
| 2023 Q3 | 6.33 Million SEK | 51.01% |
| 2022 Q2 | 4.67 Million SEK | -39.95% |
| 2022 FY | 3.86 Million SEK | 0.9% |
| 2022 Q4 | 3.86 Million SEK | 0.13% |
| 2022 Q3 | 3.86 Million SEK | -17.34% |
| 2022 Q1 | 7.77 Million SEK | 103.01% |
| 2021 Q1 | 2.4 Million SEK | -1.76% |
| 2021 FY | 3.83 Million SEK | 56.5% |
| 2021 Q3 | 2.92 Million SEK | 91.18% |
| 2021 Q4 | 3.83 Million SEK | 30.9% |
| 2021 Q2 | 1.53 Million SEK | -36.34% |
| 2020 Q2 | 3.41 Million SEK | -20.18% |
| 2020 Q1 | 4.27 Million SEK | -57.28% |
| 2020 Q4 | 2.44 Million SEK | -27.5% |
| 2020 FY | 2.44 Million SEK | -75.55% |
| 2020 Q3 | 3.37 Million SEK | -1.11% |
| 2019 FY | 10.01 Million SEK | 429.62% |
| 2019 Q4 | 10.01 Million SEK | 285.69% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 Q3 | 2.59 Million SEK | 0.0% |
| 2018 Q4 | 1.89 Million SEK | 0.0% |
| 2018 FY | 1.89 Million SEK | 55.95% |
| 2017 FY | 1.21 Million SEK | 10.22% |
| 2016 FY | 1.1 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | 44.326% |
| Amniotics AB (publ) | 10.54 Million SEK | 50.745% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -17.373% |
| BioArctic AB (publ) | 139.5 Million SEK | 96.276% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.668% |
| Genovis AB (publ.) | 98.04 Million SEK | 94.702% |
| LIDDS AB (publ) | 3.75 Million SEK | -38.311% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 95.81% |
| OncoZenge AB (publ) | 1.69 Million SEK | -205.765% |
| Saniona AB (publ) | 86.08 Million SEK | 93.965% |
| Simris Alg AB (publ) | 148.93 Million SEK | 96.512% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 87.286% |
| AcouSort AB (publ) | 10.37 Million SEK | 49.943% |
| Active Biotech AB (publ) | 13.4 Million SEK | 61.232% |
| Camurus AB (publ) | 414.81 Million SEK | 98.748% |
| Cantargia AB (publ) | 54.97 Million SEK | 90.549% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -35.355% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 71.91% |
| Mendus AB (publ) | 51.22 Million SEK | 89.859% |
| Kancera AB (publ) | 17.97 Million SEK | 71.104% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 55.096% |
| Lipum AB (publ) | 7.53 Million SEK | 31.083% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -0.716% |
| NextCell Pharma AB | 13.68 Million SEK | 62.05% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.923% |
| Xintela AB (publ) | 14.01 Million SEK | 62.933% |
| Ziccum AB (publ) | 6.38 Million SEK | 18.677% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 62.278% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -120.218% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 72.892% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 92.77% |
| CombiGene AB (publ) | 4.15 Million SEK | -24.999% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 92.695% |
| Intervacc AB (publ) | 21.68 Million SEK | 76.038% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 95.126% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 84.987% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 80.549% |
| Corline Biomedical AB | 6.78 Million SEK | 23.48% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 91.533% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 67.767% |
| Aptahem AB (publ) | 8.99 Million SEK | 42.264% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 88.751% |
| Fluicell AB (publ) | 8.91 Million SEK | 41.728% |
| Biovica International AB (publ) | 34.76 Million SEK | 85.058% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 55.477% |
| Abliva AB (publ) | 16.78 Million SEK | 69.043% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 97.579% |
| 2cureX AB (publ) | 2.93 Million SEK | -77.0% |
| I-Tech AB | 16.2 Million SEK | 67.942% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.562% |
| Cyxone AB (publ) | 4.69 Million SEK | -10.672% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 61.022% |
| Biosergen AB | 5.08 Million SEK | -2.162% |
| Nanologica AB (publ) | 79.32 Million SEK | 93.451% |
| SynAct Pharma AB | 51.83 Million SEK | 89.978% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 34.647% |
| BioInvent International AB (publ) | 90.45 Million SEK | 94.257% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 97.139% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -189.573% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 59.236% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 28.444% |